INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer's Drug Discovery

INmune Bio, Inc. Presents Preliminary

Phase I Data at 21st International Conference on Alzheimer's Drug Discovery

JOLLA, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage

immunology company focused on developing treatments that harness the patient's innate immune system to fight disease,

today announced that CJ Barnum PhD, Head of Neurosciences will present data from the ongoing biomarker directed Phase Ib

study of neuroinflammation in patients with Alzheimer's disease. The talk entitled, Phase 1b Study in AD Patients

with Neuroinflammation?, will be given today at 11:20AM

ET as part of this year's virtual 21st International Conference on Alzheimer's Drug Discovery meeting.

The trial continues to enroll patients and additional data on the Phase Ib study will be presented in the near future.

"Neuroinflammation plays an important

role in the pathophysiology of Alzheimer's disease," said CJ Barnum PhD, Head of Neurosciences at INmune Bio.

"The preliminary data, albeit in a small number of patients, demonstrate that XPro1595, when given via subcutaneous injection,

decreases neuroinflammation in the arcuate fasciculus, a white matter tract critical for the proper use of language."

White Matter Free Water (WMFW) is a novel biomarker of inflammation measured using non-invasive neuroimaging by functional MRI.

Increases in WMFW biomarkers occur in Alzheimer's patients as the disease progresses. Preliminary data in the first

6 patients showed that treatment with XPro1595 decreased WMFW on average by 40% in the arcuate fasciculus (range 20-50%).

XPro1595 is a selective inhibitor of

soluble Tumor Necrosis Factor (sTNF), a key inflammatory cytokine implicated in causing neuroinflammation in patients with neurologic

disease including treatment resistant depression, Alzheimer's disease and potentially other neurodegenerative diseases.

This Phase Ib multi-center, open label study will enroll patients with biomarkers of inflammation that have Alzheimer's disease.

Patients are treated for 12 weeks. Multiple measures of neuroinflammation are studied including biomarkers of inflammation

in blood, CSF, and breath as well as neuroimaging biomarkers studied by MRI and behavioral end-points commonly seen in AD patients

such as depression, aggression, apathy, anhedonia and sleep disorders. Measures of cognitive decline are measured as part of the

trial, but due to the small size, short duration and variable disease status at time of enrollment, changes in cognitive function

are not primary endpoints.

"The use of novel biomarkers

is a hallmark of INmune Bio's clinical development programs," said RJ Tesi MD, CEO of INmune Bio. "The use of

biomarkers may allow smarter, smaller and faster clinical trials in patients with neurodegenerative diseases."

XPro1595 is a next-generation inhibitor

of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF

(sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients

with Alzheimer's disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation

in the brain to improve cognitive function and restore neuronal communication visit this

section of the INmune Bio's website.

About INmune Bio, Inc.

Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that

target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes

dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target

of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor ), cancer (INB03 ), Alzheimer's

and treatment resistant depression (XPro595), and NASH (LIVNate ). The Natural Killer Cell Priming Platform includes INKmune

aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's

product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid

tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

Forward Looking Statements

The Company's clinical trials

are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press

release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private

Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but

are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ

materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03 , XPro1595,

LIVNate, Quellor and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved

and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are

beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual

future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating

to the Company's ability to produce more drug for clinical trials; the availability of substantial additional funding for

the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization;

and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.

These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange

Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the

Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order

to reflect any event or circumstance that may arise after the date of this release.

David Moss, CFO (858) 964-3720

Meredith Sosulski, Ph.D.

LifeSci Communications